Holen Sie sich die Stockscreener-App
208.09
0.12%
-0.27
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$208.36
Offen:
$208.82
24-Stunden-Volumen:
1.86M
Relative Volume:
0.34
Marktkapitalisierung:
$367.60B
Einnahmen:
$58.33B
Nettoeinkommen (Verlust:
$3.73B
KGV:
99.09
EPS:
2.1
Netto-Cashflow:
$18.24B
1W Leistung:
-0.50%
1M Leistung:
+9.37%
6M Leistung:
+1.50%
1J Leistung:
+6.22%
1-Tages-Spanne:
$207.87
$210.42
1-Wochen-Bereich:
$206.57
$212.45
52-Wochen-Spanne:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
208.09 | 366.65B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
736.83 | 623.33B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.94 | 429.67B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
126.93 | 242.06B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.23 | 213.09B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie’s Promising Phase 3 Study on Etentamig for Multiple Myeloma - TipRanks
AbbVie’s Latest Study on Psoriatic Arthritis: A Potential Game-Changer? - TipRanks
AbbVie’s Promising Clinical Study on ABBV-319 for B-cell Malignancies - TipRanks
AbbVie’s Ubrogepant Study: A Potential Game-Changer for Pediatric Migraine Treatment - TipRanks
What Is the Intent Behind AbbVie's Recent Acquisition Spree? - The Globe and Mail
RINVOQ's Expansion into Giant Cell Arteritis: A Strategic Catalyst for AbbVie's Immunology Growth in Canada - AInvest
Pharma giant AbbVie to spend over US$1B on Gilgamesh’s lead psychedelic - Mugglehead Magazine
AbbVie Buys Bretisilocin from Gilgamesh in $1.2B Deal to Expand Depression Drug Pipeline–Another Win in the Psychedelic Space? - geneonline.com
AbbVie to Acquire Gilgamesh's Antidepressant Bretisilocin in $1.2 Billion Deal - PharmiWeb.com
Stock Analysis | Abbvie OutlookMixed Signals Amid Optimistic Analysts and Strong Fund Flows - AInvest
Healthcare Deals This Week: AbbVie, Royalty Pharma, BeOne - Law360
Using economic indicators to assess AbbVie Inc. potentialDividend Hike & Low Risk Growth Stock Ideas - Newser
AbbVie To Buy Gilgamesh Pharmaceuticals’ Bretisilocin Therapy - Pulse 2.0
Bullish Candlestick Pattern Forms in AbbVie Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
Risk adjusted return profile for AbbVie Inc. analyzed2025 Market Trends & Safe Swing Trade Setups - Newser
AbbVie to acquire Gilgamesh’s bretisilocin - The Pharma Letter
Alopecia Areata Market to Witness Dynamic Shift as AbbVie Reports Positive Topline Results from Phase III UP-AA Trial of RINVOQ | DelveInsight - Barchart.com
What recovery options are there for AbbVie Inc.Portfolio Update Report & Precise Buy Zone Identification - Newser
AbbVie to Acquire Investigational Therapy for $2.1B - Powder & Bulk Solids
AbbVie: Plenty Of Positives (NYSE:ABBV) - Seeking Alpha
Analyzing recovery setups for AbbVie Inc. investorsChart Signals & Stepwise Swing Trade Plans - Newser
What high frequency data says about AbbVie Inc.2025 Institutional Moves & Growth Focused Stock Pick Reports - Newser
As the Market Rotates, This Healthcare ETF Is Leading the Way - Investing.com
AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment - Benzinga
AbbVie’s (ABBV) Fell in Line with the Broader Biopharmaceutical Industry - Insider Monkey
AbbVie to Acquire Gilgamesh Pharmaceutical’s Psychedelic Drug for $1.2B - Contract Pharma
AbbVie dives back into the neuro pool with a $1.2B psychedelics play - PharmaVoice
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression - Yahoo Finance
AbbVie signs to acquire Gilgamesh’s bretisilocin for $1.2bn - Pharmaceutical Technology
Key metrics from AbbVie Inc.’s quarterly data2025 Analyst Calls & Weekly High Momentum Picks - Newser
AbbVie Places $1.2 Billion Bet on Next-Generation “Non-Hallucinogenic” Psychedelic Drug - NAI500
Does AbbVie Inc. show high probability of reboundQuarterly Earnings Summary & Free Weekly Watchlist of Top Performers - Newser
How To Put $100 In Your Retirement Fund Each Month With AbbVie Stock - Yahoo Finance
AbbVie to Acquire Gilgamesh's Experimental Antidepressant for $12 Billion - AInvest
AbbVie Acquires Gilgamesh’s Psychedelic MDD Program For Up To $1.2B - HIT Consultant
AbbVie's latest acquisition targets Gilgamesh's psychedelic drug to treat depression - The Business Journals
AbbVie Buys Phase II MDD Candidate From Gilgamesh, But Not The Company - insights.citeline.com
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie to Acquire Gilgamesh’s Bretisilocin in $1.2B Psychedelic Bet - USA Herald
AbbVie Nabs Depression Drug From Gilgamesh In $1.2B Deal - Law360
AbbVie Expands Psychiatry Drug Pipeline with Acquisition of Gilgamesh Pharmaceuticals’ Bretisilocin for Major Depressive Disorder - Pharmaceutical Executive
Atai Life Sciences stock surges on AbbVie’s psychedelic drug acquisition - Investing.com
AbbVie to acquire Gilgamesh Pharma’s depression drug for up to $1.2 billion - Latest news from Azerbaijan
AbbVie to Buy Experimental Depression Drug From Gilgamesh For up to $1.2 Billion - MarketScreener
AbbVie targets psychedelic-based depression drug market with $1.2 billion deal - Reuters
AbbVie To Acquire Gilgamesh Pharmaceuticals’ Bretisilocin - citybiz
AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug - BioPharma Dive
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B - BioSpace
AbbVie makes $1.2B deal to buy Gilgamesh's psychedelic drug candidate - Crain's Chicago Business
Gilgamesh joins a second $1B+ deal with Abbvie - BioWorld MedTech
AbbVie to buy psychedelic drug from partner Gilgamesh - Endpoints News
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):